Further studies focused in investigating the role of necroptosis in gliomagenesis and tumor progression will elucidate whether MLKL and RIPK3 are not only relevant LGG prognostic biomarkers but also potential targets for therapeutic intervention, as they constitute the core machinery of necroptosis. The gene discussed is RIPK3; the disease is neoplasm.